Mind Cure Appoints Dr Ryan Hartwell As Chief Science Officer

Mind Cure Health (CSE: MCUR) has a new executive. The company this morning announced that appointment of Dr Ryan Hartwell as the firms Chief Science Officer. After months of serving on the firms scientific advisory board, Hartwell has taken the jump to lead the scientific team at the company.

A successful entrepeneur, scientist, inventor, and researcher, Hartwell appears to be highly qualified for the role. He previously founded ATS Biotech, a biomedical wound care company, while also acting as co-inventory of both FS2 and AI-001 cell therapy. Further, he also received the Vancouver Coastal Health Research Institute Award for top graduating doctoral student following the completion of his Ph.D. in experimental medicine at UBC.

Hartwell is to focus on the advancement of Mind Cure’s research and product development, and will be tasked with the role of leading efforts to research both psychoactive and psychedelic substances and their therapeutic benefits for the company. His role is to have a direct impact on establishing Mind Cure as a leader within the mental health space.

Commenting on the appointment, Hartwell stated, “From all that we have learned in studying psychedelics, the opportunity to chart a new path toward a better understanding and discovery of effective medicines provides tremendous potential to transform mental health and aging wellness.”

Mind Cure Health last traded at $0.64 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Mind Cure Health Begins Manufacturing Synthetic Ibogaine

Mind Cure Health (CSE: MCUR) this morning announced that it has begun the first stage...

Wednesday, March 3, 2021, 08:03:53 AM

Mind Cure Doubles Bought Deal Financing To $20 Million

Strong demand continues within the psychedelics space, with Mind Cure Health (CSE: MCUR) announcing earlier...

Friday, January 22, 2021, 02:07:33 PM

Mind Cure To Launch Psychedelic Assisted Mental Health Therapy Centre

Mind Cure Health (CSE: MCUR) is the latest issuer to become involved in operating psychedelic-assisted...

Thursday, December 10, 2020, 07:26:09 AM

Mind Cure Appoints Dr Wolfram Tetzlaff To Advisory Board

It appears that Mind Cure Health (CSE: MCUR) is not quite yet done compiling its...

Tuesday, October 13, 2020, 09:01:47 AM

Mind Cure Sees Warrants Approved For Trading

Mind Cure Health (CSE: MCUR) is looking to provide a boost to its liquidity for...

Thursday, February 11, 2021, 09:32:23 AM